Biotech News News 1 January 2026

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

NEW YORK, Jan 5, 2026, 15:54 EST — Regular session Shares of Immunome, Inc. fell 5.3% to $19.72 in late afternoon trading on Monday, underperforming U.S. biotech peers. The SPDR S&P Biotech ETF slid 1.1% and the iShares Nasdaq Biotechnology

5 January 2026

Biotech News·Company Earnings·Financial Analysis·Investment Updates·Stock Market

Argenx stock slides 5% on CEO handover plan — what investors watch next

New York, Jan 5, 2026, 15:30 EST — Regular session Shares of argenx fell about 5% on Monday after the immunology drugmaker said Chief Operating Officer Karen Massey will succeed co-founder Tim Van Hauwermeiren as CEO, with Van Hauwermeiren set

5 January 2026

Biotech News·Financial Analysis·Investment Strategies·Stock Market

Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next

New York, January 5, 2026, 15:09 EST — Regular session Shares of Spyre Therapeutics Inc fell 2.7% to $29.75 in afternoon trading on Monday, extending a choppy start to the year for smaller biotechnology names. The stock traded between $28.02

5 January 2026

Biotech News·Financial Trends·Investing Tips·Stock Market

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

New York, January 5, 2026, 1:09 PM ET — Regular session Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged

5 January 2026

Biotech News·Healthcare Industry·Investment Analysis·Stock Market

Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open

NEW YORK, Jan 4, 2026, 11:15 ET — Market closed Spyre Therapeutics shares fell 6.6% to $30.58 on Friday, then ticked up about 2% in after-hours trading, as U.S. markets headed into the weekend. Yahoo Finance With markets shut on

4 January 2026

Biotech News·Financial Updates·Investment Analysis·Market Trends·Stock Market

Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus

NEW YORK, Jan 3, 2026, 20:43 ET — Market closed Kymera Therapeutics shares slid on Friday, ending down 6.6% at $72.76 as the biotech underperformed its sector even as the broader market started 2026 on a mixed note. The move

4 January 2026

Biotech News·Financial Analysis·Investment Trends·Stock Market

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

NEW YORK, January 3, 2026, 20:15 ET — Market closed Spyre Therapeutics, Inc. shares fell 6.6% on Friday to $30.58, finishing the first U.S. trading day of 2026 near the lower end of the session’s $30.11-$33.31 range. The stock remains

4 January 2026

Biotech News·Clinical Trials·Financial Updates·Investment Analysis·Stock Market

Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next

NEW YORK, Jan 2, 2026, 15:39 ET — Regular session Kymera Therapeutics Inc (KYMR.O) shares fell nearly 7% on Friday afternoon after a regulatory filing disclosed a year-end sale by Chief Executive Nello Mainolfi. Kymera was down 6.9% at $72.42,

2 January 2026

Biotech News·Company Analysis·Investor Insights·Stock Market

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

NEW YORK, January 1, 2026, 21:21 ET — Market closed With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc (ARQT) last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged

2 January 2026

Biotech News·Earnings Reports·FDA Updates·Stock Market

INBS stock today: Intelligent Bio Solutions swings after $10 million raise follows new manufacturing deal

NEW YORK, January 1, 2026, 11:36 ET — Market closed Intelligent Bio Solutions Inc. shares swung sharply into year-end after the medical-device maker said it would raise about $10 million in a private placement, prompting a drop in after-hours trading

1 January 2026

Biotech News·Company Updates·Financial Analysis·Investment·Stock Market

Corcept Therapeutics (CORT) stock sinks after FDA rebuff; relacorilant outlook resets

NEW YORK, January 1, 2026, 10:45 ET — Market closed. Corcept Therapeutics Inc (CORT) shares last ended Wednesday down 50.4% at $34.80 after the company said U.S. regulators were not ready to approve its drug relacorilant for a form of

1 January 2026

Biotech News·FDA Updates·Investment Analysis·Pharmaceutical Industry·Stock Market

Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus

NEW YORK, January 1, 2026, 10:07 ET — Market closed Disc Medicine, Inc. shares rose 3.3% to $79.41 in the last U.S. trading session of 2025, before Wall Street shut on Thursday for the New Year’s Day holiday. Investors are

1 January 2026

Biotech News·FDA Updates·Healthcare Stocks·Investment Strategies·Stock Market

Biotech News News 1 January 2026 - 5 January 2026